Satish R. Raj, MD, FACC
Professor of Cardiac Sciences
University of Calgary

Printed as of 11/19/2026

Disclosures

Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Elsevier	Consultant Fees/Honoraria	Modest (< $5,000)	*Arrhythmias and Clinical EP*
Lumia Health	Consultant Fees/Honoraria	Modest (< $5,000)	*Arrhythmias and Clinical EP*
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
Regeneron	Consultant Fees/Honoraria	Modest (< $5,000)	*Arrhythmias and Clinical EP*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (5)

Non-Commercial Enity Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Canadian Cardiovascular Society *† I am on the Board*	Officer, Director, Trustee, or other Fiduciary Role	None ($0)	*General Cardiology*
Canadian Institutes of Health Research	Research/Research Grants *‡ Understanding the Physiological Effects of Wearable Vagal Neuromodulation in Postural Orthostatic Tachycardia Syndrome*	Significant (>= $5,000)	*Arrhythmias and Clinical EP*
Dysautonomia International *† Non-profit patient advocacy group*	Research/Research Grants *‡ -LDN for POTS RCT; Ivabradine vs Propranolol Comparative Effectiveness study; CMR in POTS study*	Significant (>= $5,000)	*Arrhythmias and Clinical EP*
Heart and Stroke Foundation of Canada *† Not commercial; Foundation Peer Reviewed Grant*	Research/Research Grants	Significant (>= $5,000)	*Arrhythmias and Clinical EP*
Standing Up to POTS *† Non-profit patient advocacy group*	Research/Research Grants *‡ Effect of Hyperventilation on Tachycardia in POTS*	Significant (>= $5,000)	*Arrhythmias and Clinical EP*

Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
Product Surveillance Registry	MEDTRONIC	
PHASE 2 DB PC SINGLE-DOSE STUDY OF PD, PK, SAFETY, AND TOLERABILITY OF REGN7544, AN NPR1 ANTAGONIST mAB, IN POTS	Regeneron	
Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Theravance, Inc.	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2026	Did motor vehicle accident contribute to POTS Symptoms	Plaintiff	Injury post MVA; rules to collect from auto insurance requires a lawuit	Significant (>= $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/12/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/12/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/12/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/12/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.